Sun Li-Chao-Yue, Li Wen-Shu, Chen Wei, Zhao Dan-Qi, Zhang Xin, Li Chun-Xing, Ren Zhao
Pharmacy Department, Aerospace Center Hospital, Beijing, People's Republic of China.
Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China.
J Multidiscip Healthc. 2025 Sep 11;18:5743-5758. doi: 10.2147/JMDH.S544626. eCollection 2025.
Edaravone is a potent free-radical scavenger and antioxidant that has been widely investigated for its therapeutic potential in neurodegenerative diseases and oxidative stress-related conditions. Although previous studies have explored its molecular structure, pharmacological effects, and clinical applications, a comprehensive bibliometric analysis of its research trends and future directions remains lacking.
This study employed bibliometric methods to analyze edaravone-related publications from 2000 to 2024, using the Web of Science Core Collection database. The analysis examined publication trends; contributions by countries, institutions, and authors; and keyword clustering. Data visualization tools, such as CiteSpace and VOSviewer, were utilized to identify research clusters and emerging trends in edaravone research.
The findings revealed a significant increase in edaravone-related publications, with China, Japan, and the United States as the leading contributors. Notable researchers, including Abe K and Yoshino H, have made substantial contributions to this field. Four major research clusters were identified: free radical scavenging, cerebral infarction, amyotrophic lateral sclerosis, and oxidative stress. Emerging trends suggest a growing interest in edaravone dexbornel for acute ischemic stroke treatment, as well as its potential applications in blood-brain barrier interactions and Alzheimer's disease.
This bibliometric analysis highlights the growing interest in edaravone and its potential clinical application, particularly in neuroprotection. While this study provides valuable insights into current research trends, future studies should incorporate a broader range of sources and languages to obtain a more comprehensive understanding of the impact and scope of edaravone.
依达拉奉是一种强效的自由基清除剂和抗氧化剂，已针对其在神经退行性疾病和氧化应激相关病症中的治疗潜力进行了广泛研究。尽管先前的研究已经探索了其分子结构、药理作用和临床应用，但仍缺乏对其研究趋势和未来方向的全面文献计量分析。
本研究采用文献计量方法，利用科学引文索引核心合集数据库分析2000年至2024年与依达拉奉相关的出版物。分析考察了发表趋势；国家、机构和作者的贡献；以及关键词聚类。利用CiteSpace和VOSviewer等数据可视化工具来识别依达拉奉研究中的研究集群和新出现的趋势。
研究结果显示，与依达拉奉相关的出版物数量显著增加，中国、日本和美国是主要贡献者。包括阿部健和吉野浩在内的知名研究人员对该领域做出了重大贡献。确定了四个主要研究集群：自由基清除、脑梗死、肌萎缩侧索硬化症和氧化应激。新出现的趋势表明，人们对右莰醇依达拉奉治疗急性缺血性中风的兴趣日益增加，以及其在血脑屏障相互作用和阿尔茨海默病中的潜在应用。
这项文献计量分析突出了对依达拉奉及其潜在临床应用，特别是在神经保护方面的兴趣日益增长。虽然本研究为当前的研究趋势提供了有价值的见解，但未来的研究应纳入更广泛的来源和语言，以更全面地了解依达拉奉的影响和范围。
